Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13M with net income of −$5M.
Q3 2026 key financials · XBRL
- Revenue
- $13M
- +18.6% QoQ
- Net income
- −$5M
- +6.8% YoY · +76.2% QoQ
- Operating margin
- -96.4%
- EPS (diluted)
- −$0.08
- +33.3% YoY · +77.8% QoQ
Source: XBRL data from the ABEONA THERAPEUTICS INC. (ABEO) Q3 2026 10-Q on SEC EDGAR. USD.
ABEONA THERAPEUTICS INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $13.5M, versus $0 YoY, entirely from ZEVASKYN product sales
- Q3 operating loss $13.0M vs $24.0M, operating margin -96.3% vs not meaningful
- ZEVASKYN, sole product line, generated $13.5M revenue and $5.7M cost of sales
- Cash resources $134.9M at September 30, 2026, operating cash outflow $45.6M through nine months
- Outlook: cash sufficient through next 12 months, additional funding potentially needed for development and commercialization
Risk Factors
- Newly added financing risk: November 6 private placement expected to issue 6,400,000 shares and 1,600,043 pre-funded warrants
- Most material update, commercial risk: ZEVASKYN revenue reached $33.591 million, but manufacturing, 84-hour shelf-life, and treatment-center execution remain critical
- Regulatory risk: FDA approval of Ultragenyx’s ABO-102 in September 2026 creates royalty eligibility, but payments remain subject to sales-based constraints
- Operational risk: APT-1011 acquisition adds an EoE development program requiring FDA approval before $30 million milestone eligibility
- Liquidity risk: cash and equivalents declined to $66.284 million, with $11.111 million debt principal due by December 31, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ABEONA THERAPEUTICS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.